Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Positive inotropic/vasodilator agents.

W S Colucci1

  • 1Harvard Medical School, Boston, Massachusetts.

Cardiology Clinics
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Beta-adrenergic sympathomimetic agents and phosphodiesterase inhibitors increase cyclic AMP for positive inotropic effects in myocardial failure. Their short-term use is valuable, but long-term efficacy for congestive heart failure remains investigational.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.

British journal of pharmacology·2007
Same author

Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study.

Heart (British Cardiac Society)·2006
Same author

The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways.

Archives des maladies du coeur et des vaisseaux·2005
Same author

Adrenergic regulation of cardiac myocyte apoptosis.

Journal of cellular physiology·2001
Same author

Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes.

Circulation research·2001
Same author

Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction.

Circulation research·2001
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiology
  • Biochemistry

Background:

  • Myocardial failure, including congestive heart failure, presents a significant clinical challenge.
  • Current therapeutic strategies aim to improve cardiac contractility and reduce cardiac workload.

Purpose of the Study:

  • To review the mechanisms and acute efficacy of beta-adrenergic sympathomimetic agents and phosphodiesterase inhibitors in managing myocardial failure.
  • To assess the current evidence regarding the long-term application of these agents in congestive heart failure.

Main Methods:

  • Review of pharmacological agents including dobutamine, dopamine, amrinone, milrinone, and enoxamone.
  • Analysis of their effects on myocardial cyclic AMP levels and vascular tone.
  • Evaluation of their established role in acute versus investigational role in chronic heart failure management.

Related Experiment Videos

Main Results:

  • Beta-adrenergic sympathomimetic agents and phosphodiesterase inhibitors increase myocardial cyclic AMP, leading to a positive inotropic effect.
  • Phosphodiesterase inhibitors also induce significant vasodilation.
  • Both drug classes demonstrate utility in the acute management of myocardial failure.

Conclusions:

  • These agents are effective for short-term treatment of acute myocardial failure.
  • The long-term therapeutic benefit for congestive heart failure is not yet established and requires further investigation.